Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Randomised, Phase II Trial of Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

NCT06954480 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT06954480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06954480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Randomised, Phase II Trial of Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
Lead sponsor
Queen Mary University of London
Phase
Phase 2
Overall status
Recruiting
Start date
October 27, 2025
Completion date
February 28, 2030
Enrollment
140 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer